Introduction {#s1}
============

Postoperative pain remains a great challenge. A survey revealed that 30% of 5,703 ambulatory patients experienced moderate-to-severe postoperative pain and that laparoscopic procedures were some of the most common reasons underlying this pain ([@mcgr2004]). In addition to causing unnecessary suffering and discomfort, poorly controlled postoperative pain may also lead to other morbidities, such as ischemic myocardial events ([@rawa1998]).

Parecoxib, a cyclooxygenase-2 selective inhibitor commonly used in the postoperative period, exerts anti-inflammatory effects by inhibiting prostaglandin synthesis ([@fitz2001]). Although the effect of parecoxib on pain intensity has been reported ([@lloy2009]), there is a lack of information regarding its effect on the duration of postoperative pain. Considering the contraindications of parecoxib, we were seeking for a substitution of parecoxib in postoperative pain management. Methylprednisolone is a glucocorticoid with anti-inflammatory activities. Although glucocorticoids reportedly inhibit spinal cord neuronal nociceptive afferent input and prevent peripheral and central sensitization ([@wool1993]), the effects of methylprednisolone on postoperative pain remain controversial. Several trials have demonstrated its analgesic effects ([@lunn2011]; [@acha2013]); however, contradictory results have also been reported ([@aaba2014]).

We hypothesized that both parecoxib and methylprednisolone alleviate postoperative inflammatory pain owing to their anti-inflammatory activities. This randomized controlled trial compared the effects of parecoxib, methylprednisolone, and placebo on the duration of acute postoperative pain after laparoscopic-assisted vaginal hysterectomy (LAVH). The study also assessed postoperative pain intensity, analgesic consumption, nausea, vomiting, wound infection, delayed wound healing, presence of fever, gastrointestinal recovery, inflammatory factors, blood glucose levels, and length of hospital stay (LOS).

Methods {#s2}
=======

Study Design {#s2_1}
------------

This prospective, randomized controlled trial with patient and outcome assessor blinding was approved by the Internal Review Board of Xuanwu Hospital of Capital Medical University, Beijing, China, and was conducted from September 2016 to September 2017. All experimental procedures used were performed in accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki. Verbal and written informed consents were obtained from all the included patients. This trial was registered at the Chinese Clinical Trial Registry (ChiCTR-IOR-16009152).

Patients {#s2_2}
--------

Patients scheduled for elective LAVH under general anesthesia were included in this study. The other inclusion criteria were as follows: age 18--65 years ([@mcgr2004]) and American Society of Anesthesiologists (ASA) physical status classification of I to II ([@rawa1998]). The exclusion criteria were as follows: participation in other trials ([@mcgr2004]), cancer ([@rawa1998]), infection ([@fitz2001]), smoking history ([@fitz2001]), body mass index of \>35 kg/m^2^ ([@lloy2009]), alcohol or drug use ([@wool1993]), chronic pain ([@lunn2011]), contraindication for study medication use ([@acha2013]), and refusal to participate ([@aaba2014]).

Randomization and Blinding {#s2_3}
--------------------------

The included patients were randomly assigned to three groups (Groups P, M, and S) in a 1:1:1 ratio. Randomization was performed *via* an online randomization software (<https://tools.medsci.cn/rand>) prepared by an investigator with no clinical involvement in this study. After randomization, based on the randomization list, the study medication was pre-packed by the pharmacy in consecutively numbered boxes. The patients received the treatment corresponding to their group. Information regarding the treatment was concealed in consecutively numbered, sealed, opaque envelopes to enable un-blinding in case of acute complications. The patients and research personnel responsible for outcome assessment were blinded to the groups. The randomization code was broken only after patient enrollment and follow-up had ended.

Interventions {#s2_4}
-------------

The anesthesia management protocol was standardized among the groups. Heart rate, non-invasive blood pressure level, pulse oxygen saturation level, nasopharyngeal temperature, end-tidal carbon dioxide level, and bispectral index (BIS) were routinely monitored. Anesthesia was induced using propofol (1.5--2.5 mg/kg), remifentanil (1.5 µg/kg), and rocuronium (0.6 mg/kg). All patients were intubated with an endotracheal tube and ventilated with 40% oxygen in an oxygen--air mixture. Anesthesia was maintained with propofol (4--6 mg/kg/h) and remifentanil (0.2--0.4 µg/kg/min). The propofol infusion was titrated to maintain the BIS value between 40 and 60.

Group P received 40 mg parecoxib sodium (Dynastat, Pfizer, Kalamazoo, USA) in 1 ml of normal saline solution (0.9%) 30 min prior to the end of surgery. Group M received methylprednisolone (Solu-Medrol, Pfizer, Puurs, Belgium) at 1 mg/kg before induction and 1 ml of normal saline solution (0.9%) 30 min prior to the end of surgery. Group S received 1 ml of normal saline solution (0.9%) before induction as well as 30 min prior to the end of surgery. All groups received 0.1 mg/kg of oxycodone (Oxynorm, Mundipharma, Nottinghamshire, UK) and 4 mg of ondansetron 30 min prior to the end of surgery.

Postoperative pain was assessed using the numeric rating scale (NRS; score range 0--10; 0, no pain; 10, worst imaginable pain). Intravenous oxycodone (0.05 mg/kg) was administered if the pain exceeded an NRS score of 3. Postoperative nausea or vomiting was treated with intravenous ondansetron (4 mg). If ondansetron was ineffective, metoclopramide (10 mg) was administered. Patients administered other analgesics, antiemetics, or sedatives during the first 48 h postoperatively were excluded from the study.

Blood Samples {#s2_5}
-------------

Venous blood samples were collected before induction (T0, baseline), at the end of surgery (T1), as well as 24 (T2) and 48 h (T3) after surgery. The samples were used for analyzing serum C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) levels. The samples were centrifuged for 15 min at 3,000 rpm, and the supernatants were frozen at −80°C until laboratory analysis was performed.

Data Collection {#s2_6}
---------------

Patient demographic data, including age, body mass index, ASA physical status, and preoperative diagnosis, were recorded 1 day prior to the scheduled surgery. The patients were preoperatively trained by research personnel regarding the use of the NRS. Pain and adverse effects, such as nausea, vomiting, wound infection, delayed wound healing, and fever, were evaluated at the end of surgery and at 1, 2, 3, 4, 6, 12, 24, and 48 h postoperatively. Pain was assessed using the NRS during coughing (patients were told to cough) and at rest, as described previously ([@lusc2010]; [@hwan2014]; [@klei2017]). The duration of acute postoperative pain (from the end of surgery to the time point when the NRS score was 0) during coughing and at rest as well as the location of pain (incisions, abdomen, or no pain) were recorded. If the NRS score was \>0 at discharge, the duration of pain was calculated from the end of surgery to discharge. To reduce the risk of adverse outcomes resulting from the insufficient postoperative pain control and enhance the quality of patients' life, our target was to reduce or eliminate postoperative pain before discharge ([@apfe2012]). Considering the potential glucose-increasing effect of methylprednisolone, blood glucose levels were measured before induction (T0), at the end of surgery (T1), and at 1 h after surgery using a glucometer (Accu-Chek Performa, Accu-Chek Inform II test strips; Roche Diagnostics, Indianapolis, IN, USA). The serum CRP and TNF-α levels were determined using an enzyme-linked immunosorbent assay (Biokits Tech, Inc., Beijing, China), which was performed according to the manufacturer's instructions. All samples were analyzed at a dilution resulting in levels within the standard curve range.

The primary outcome was the duration of pain (during coughing or at rest) after surgery. The secondary outcomes were pain intensity during coughing or at rest 0--48 h postoperatively (NRS), oxycodone consumption, adverse effects (nausea, vomiting, wound infection, delayed wound healing, and fever), gastrointestinal recovery, serum CRP and TNF-α levels, blood glucose levels, and LOS.

Statistical Analysis {#s2_7}
--------------------

The study was powered for the primary outcome. According to a pilot study, a sample size of 29 patients in each group would be required (90% power; alpha error of 0.05; two-sided test) to detect a difference in the duration of pain during coughing \[Group S, 31.5 (5.7) h vs. Group P, 7.5 (8.4) h vs. Group M, 27.0 (15.4)\]. Assuming a 20% dropout rate, we planned to recruit a total of 105 patients.

Data are presented as mean and SD, median and interquartile range (IQR), or frequency, as appropriate. Continuous outcome variables were tested for normality of distribution *via* visual inspection and the Kolmogorov--Smirnov test. Data that followed a normal distribution (demographic and surgical data, serum CRP and TNF-α levels, flatus time, LOS, and blood glucose levels) were analyzed using analysis of variance (ANOVA). Relationships between the duration of pain and inflammatory factors were analyzed using Spearman's rank correlation coefficient. Data that followed a non-normal distribution (duration of pain after surgery, NRS pain score, and oxycodone consumption) were analyzed using the Kruskal--Wallis test. If statistical significance was observed in the analyses among the three groups, the differences in data between the groups were further assessed using the Student--Newman--Keuls test or Mann--Whitney *U*-test. Categorical data (ASA, incidence of adverse effects, and complications) were analyzed using the chi-square test. All statistical analyses were performed using SPSS version 19.0 for Windows (IBM Corp., Armonk, NY, USA). A *p*-value of \<0.05 was considered statistically significant.

Results {#s3}
=======

A total of 202 consecutive patients scheduled for LAVH were considered for inclusion, and eventually, 105 patients were included in this study and randomly assigned to three groups ([**Figure 1**](#f1){ref-type="fig"}). Of the 105 patients, 11 were excluded from the analysis (three for extensive surgery, three for refusing to be exsanguinated, and five for unexpected postoperative medications), and consequently, 94 patients were finally included. Of the 94 patients, 30, 34, and 30 were included in Groups P, M, and S, respectively. Patient characteristics are summarized in [**Table 1**](#T1){ref-type="table"}. No significant differences were observed in the demographic and surgical data among the study groups.

![Study flow diagram. BMI, body mass index.](fphar-10-00689-g001){#f1}

###### 

Patients' demographic characteristic and surgical data.

  Characteristics                      Group P           Group M           Group S           *p* value
  ------------------------------------ ----------------- ----------------- ----------------- -----------
  Age, y                               52.5 (7.3)        51.2 (6.3)        50.2 (6.5)        0.403
  ASA group, I/II                      20/10             23/11             19/11             0.931
  BMI, kg/m^2^                         24.2 (2.7)        25.3 (3.3)        26.1 (3.1)        0.055
  Duration of operation, min           78.1 (25.5)       72.8 (20.1)       79.1 (28.7)       0.548
  Total remifentanil consumption, μg   1,623.7 (450.4)   1,621.9 (407.0)   1,740.7 (901.0)   0.692

Data are mean (SD) or frequencies. BMI, body mass index; ASA, American Society of Anesthesiologists physical status.

The duration of pain of the different groups following surgery is presented in [**Table 2**](#T2){ref-type="table"}. The duration of pain during coughing after surgery was significantly lower in Group P \[26.0 (5.8--48.0) h\] than in Group M \[48.0 (30.0--55.5) h; *p* = 0.028\] and Group S \[48.0 (36.0--58.5) h; *p* = 0.013\]; the durations were similar between Groups M and S (*p* = 0.714). The duration of pain during rest was significantly lower in Group P than in Group M (*p* = 0.008) and Group S (*p* = 0.008); the durations were similar between Groups M and S (*p* = 0.939).

###### 

Duration of pain during coughing and at rest.

  Duration of pain     Group P            Group M             Group S             *p* value
  -------------------- ------------------ ------------------- ------------------- -----------
  During coughing, h   26.0 (5.8--48.0)   48.0 (30.0--55.5)   48.0 (36.0--58.5)   0.025
  At rest, h           5.5 (3.8--21.0)    24.0 (6.0--28.0)    22.0 (5.8--36.0)    0.009

Data are median and IQR (interquartile range).

Pain intensities following surgery in the three groups are shown in [**Figure 2**](#f2){ref-type="fig"}. Pain intensities (NRS scores) were measured at 0, 1, 2, 3, 4, 6, 12, 24, and 48 h after surgery. At 12 h after surgery, visceral pain during coughing was significantly lower in Group P than in Group S (*p* = 0.018). At 24 h after surgery, visceral pain during coughing was significantly lower in Group P than in Group M (*p* = 0.004) and Group S (*p* = 0.014) ([**Figure 2A**](#f2){ref-type="fig"}). At 12 h after surgery, visceral pain at rest was significantly lower in Group P than in Group M (*p* = 0.010) and Group S (*p* = 0.005) ([**Figure 2B**](#f2){ref-type="fig"}). The NRS scores of incisional pain during coughing and at rest were similar among all the groups ([**Figure 2C and D**](#f2){ref-type="fig"}).

![NRS score following surgery. **(A)** NRS score of visceral pain intensity during coughing in 3 groups: parecoxib (Group P), methylprednisolone (Group M), and placebo (Group S). **(B)** NRS score of visceral pain intensity at rest. **(C)** incisional pain during coughing. **(D)** incisional pain at rest. Asterisks represented statistically significant difference between the groups: \**p* \< 0.05.](fphar-10-00689-g002){#f2}

The secondary outcomes are presented in [**Table 3**](#T3){ref-type="table"}. Postoperative oxycodone consumption was similar among the three groups (*p* = 0.099). There were no significant differences in the baseline serum CRP and TNF-α levels among the three groups before surgery. Repeated-measures ANOVA for CRP levels revealed a significant main effect of treatment (*F* = 125.8; *p* \< 0.001), a significant effect of time (*F* = 69.2, *p* \< 0.001), and a time-by-treatment interaction (*F* = 3.4; *p* = 0.004). At 24 and 48 h after surgery, the serum CRP level was significantly lower in Group M than in Groups P or S (24 h, *p* \< 0.001; 48 h, *p* = 0.005). The main effect of treatment on the TNF-α levels yielded a significant *F* ratio (*F* = 97.6; *p* \< 0.001) and a significant effect of time (*F* = 39.0; *p* \< 0.001); however, the time-by-treatment interaction was not significant (*F* = 0.04; *p* = 0.715). Direct comparisons indicated that compared with the preoperative levels in all groups, the TNF-α levels significantly increased at 24 and 48 h after surgery. The TNF-α levels among the three groups at each time point demonstrated no significant differences. No correlations were observed between the CRP or TNF-α level and the duration of pain during coughing (CRP: *p* ~T1~ = 0.498, *p* ~T2~ = 0.751, *p* ~T3~ = 0.856; TNF-α: *p* ~T1~ = 0.306, *p* ~T2~ = 0.317, *p* ~T3~ = 0.244) and at rest (CRP: *p* ~T1~ = 0.350, *p* ~T2~ = 0.251, *p* ~T3~ = 0.770; TNF-α: *p* ~T1~ = 0.966, *p* ~T2~ = 0.219, *p* ~T3~ = 0.106).

###### 

Secondary outcomes of study.

                                               Group P              Group M              Group S              *p* value
  -------------------------------------------- -------------------- -------------------- -------------------- -----------
  Oxycodone consumption, mg                    2.3 (3)              2.0 (6.5)            4.8 (10)             0.099
  Serum CRP level                                                                                             
  CRP, T0, ng/mL                               615.6 (724.3)        520.8 (513.1)        546.8 (642.6)        0.827
  CRP, T1, ng/mL                               622.5 (731.3)        483.9 (444.9)        536.5 (606.7)        0.652
  CRP, T2, ng/mL                               5,859.7 (3387.5)\*   2,822.0 (2361.3)\*   5,408.7 (3456.3)\*   0.000
  CRP, T3, ng/mL                               8,699.3 (6283.6)\*   4,893.7 (4118.4)\*   9,375.7 (6915.8)\*   0.005
  Serum TNF-α level                                                                                           
  TNF-α, T0, pg/mL                             18.9 (18.6)          17.3 (16.7)          16.2 (5.8)           0.771
  TNF-α, T1, pg/mL                             18.6 (3.6)           16.3 (15.5)          16.3 (7.8)           0.791
  TNF-α, T2, pg/mL                             40.5 (29.0)\*        32.9 (30.7)\*        33.1 (16.6)\*        0.443
  TNF-α, T3, pg/mL                             52.1 (44.3)\*        43.1 (38.1)\*        41.8 (22.7)\*        0.485
  PONV, *n* (%)                                12 (40)              10 (29)              14 (47)              0.357
  Flatus time, h                               24.2 (5.7)           26.1 (6.7)           24.9 (5.4)           0.450
  LOS, days                                    4.5 (0.9)            4.5 (1.0)            4.8 (1.3)            0.317
  BG, T0, mmol/L                               5.4 (0.8)            5.4 (0.9)            5.7 (1.3)            0.529
  BG, T1, mmol/L                               5.4 (0.8)            5.9 (1.1)            5.4 (1.1)            0.042
  BG, 1 h after the end of operation, mmol/L   5.9 (1.1)            6.9 (1.5)            6.0 (1.3)            0.001

Data are mean (SD) or median and IQR (interquartile range) or frequencies. \*Compared with T0, p \< 0.05. CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; LOS, length of hospital stay; BG, blood glucose; PONV, postoperative nausea and vomiting.

Postoperative nausea and vomiting (PONV) occurred in 12 patients from Group P, 10 from Group M, and 14 from Group S. The incidence of PONV was similar among the three groups (*p* = 0.357). The flatus time and LOS were similar among the three groups (*p* = 0.450 and *p* = 0.317, respectively). The blood glucose level before induction (T0) was also similar among the three groups (*p* = 0.529). However, the blood glucose levels at the end of surgery and at 1 h after surgery were significantly higher in Group M than in Groups P or S. No patient from Group P, one patient from Group M, and three patients from Group S had fever (axillary temperature \> 38°C) or leukocytosis (leucocyte count \> 10 × 10^9^/L) after surgery. No patient had wound infection or delayed wound healing.

Discussion {#s4}
==========

The present trial demonstrated that intraoperative administration of parecoxib sodium 40 mg (Group P) significantly shortened the duration of pain during coughing and at rest after LAVH and that it reduced the intensity of acute visceral but not incisional pain. In Group P, the duration of pain during coughing and at rest was 26 and 5.5 h, respectively, and the mean LOS after surgery was 2.6 days, indicating that Group P achieved the clinical target of "eliminate postoperative pain before discharge" ([@apfe2012]).

Few trials have mentioned the impact of parecoxib on the duration of acute postoperative pain; the mechanism associated with the effect of parecoxib on the pain process remains unclear. The analgesic effect of parecoxib is attributable to the blockage of the arachidonic acid cascade and production of prostaglandins ([@fitz2001]), the reductions in both basal and enhanced prostaglandin release in the spinal cord ([@vane2001]), and the further prevention of peripheral sensitization ([@wool1993]). Prostaglandins, which are metabolites of arachidonic acid, play important roles in modulating inflammatory and nociceptive processes ([@vane1998]), directly exciting nociceptors, and potentiating the sensitizing effects of other pain mediators ([@vane2001]; [@mori2005]; [@wang2007]). A study concerning the mechanism of PGE2-prolonged nociceptor sensitization reported that synthesis stimulation and anterograde axonal trafficking to increase EP4 availability may be one explanation ([@stja2014]). Considering our result that the duration of pain was shortened with parecoxib, we suspect that the inhibition of PGE2-prolonged sensitization of the nociceptive dorsal root ganglion by parecoxib will help reduce pain processing.

The potential side effects should be considered when choosing analgesics. Because parecoxib is contraindicated in patients with ischemic heart disease, cerebrovascular disease, peripheral vascular diseases, congestive heart failure, history of sensitivity to sulfonamides, and bypass operation of the coronary artery ([@lloy2009]), a substitute drug is needed. It still remains unclear whether glucocorticoids can be used as substitutes for parecoxib ([@lunn2011]; [@aaba2014]). Thus, in this study, we used methylprednisolone and compared its effects with those of parecoxib and placebo.

The analgesic effects of glucocorticoids after laparoscopy surgery are controversial. One study demonstrated that dexamethasone at 0.1 mg/kg reduced pain at 2, 6, and 12 h after surgery ([@moht2014]). Another study found no differences between placebo and dexamethasone at different doses (5, 10, and 15 mg) ([@joke2009]). A meta-analysis involving 5,796 patients from 45 studies concluded that those who received dexamethasone (1.25--20 mg) had lower pain scores at 2 and 24 h after surgery, a longer time to the first dose of analgesic, and reduced opioid consumption with no differences among doses ([@wald2013]). Because methylprednisolone has a more rapid onset time than has dexamethasone and a perioperative single dose of methylprednisolone does not increase the occurrence of adverse effects ([@saue2000]), we used methylprednisolone instead of dexamethasone in this study.

Data concerning the analgesic effects of methylprednisolone are sparse and inconsistent ([@lunn2011]; [@acha2013]; [@aaba2014]). Methylprednisolone has shown analgesic effects in orthopedic and dental surgeries. Rytter et al. claimed that administration of 125 mg of systemic methylprednisolone could reduce postsurgical pain and decrease opioid requirement after knee arthroplasty ([@rytt2017]). This pain-reducing effect has also been reported in third molar surgery ([@acha2013]). In contrast, [@aaba2014] randomized 59 patients undergoing abdominal hysterectomy to receive 125 mg of methylprednisolone or saline and assessed postoperative pain in the first 24 h at rest and during mobilization using a visual analog scale. Aabakke et al. found that methylprednisolone had no effect on postoperative pain after surgery, and this finding corroborates with our results. The pain-reducing effects of methylprednisolone in orthopedic and dental surgeries and not gynecologic surgery may be associated with its anti-inflammatory effects that reduce local swelling and edema ([@holt2002]; [@lunn2011]).

Some studies have suggested the opioid-sparing effects of parecoxib ([@ng2003]; [@pars2016]) and glucocorticoids ([@joke2009]; [@deol2011]; [@moht2014]). However, our study demonstrated a tendency of lower oxycodone consumption in both the parecoxib and methylprednisolone groups compared with the saline group (median, 2.3 vs. 2.0 vs. 4.8 mg), but no statistical difference was noted between the groups. Our sample size was calculated according to the primary outcome (duration of postoperative pain) and was not powered to demonstrate a difference in the oxycodone consumption. A larger sample size may help identify a difference in oxycodone consumption.

Surgical trauma induces an inflammatory state that is characterized by the local release of inflammatory proteins and cytokines, which enter the circulation and systemically spread ([@baut2010]). TNF-α is a major mediator that responds to tissue damage secondary to surgery ([@hack1998]). CRP is an acute phase reactant, and its level increases in response to inflammatory stimuli ([@rosa2001]). Inflammation may enhance postoperative pain ([@gask2017]); however, in the present study, we found no correlations between the levels of postoperative inflammatory cytokines (TNF-α and CRP) and the duration of pain. Our findings suggest that the pain process is irrelevant with respect to these two systemic inflammatory indicators. Considering that parecoxib shows antinociceptive and anti-inflammatory effects by inhibiting prostaglandin synthesis ([@ricc2011]), prostaglandins could be highly sensitive inflammatory mediators and major enhancers of nociceptive responses to surgery ([@brow2018]). Further studies are required to confirm the relationships among prostaglandins, surgery, and pain.

Elevated blood glucose levels and immunosuppression are potential concerns for glucocorticoid use. A previous meta-analysis investigated these risks and concluded that perioperative administration of glucocorticoids did not affect wound infection but caused a clinically insignificant increase in the peak glucose level in noncardiac surgery ([@tone2017]). There is no conclusive evidence that suggests that a single glucocorticoid dose is associated with hyperglycemia, and this may contribute to postoperative morbidity ([@saue2000]). In the present study, 1 mg/kg of methylprednisolone increased the postoperative glucose level when compared with the level in the control group; however, this did not seem to be clinically significant. In addition, methylprednisolone did not increase the risk of fever or delayed wound healing, which is similar to the findings of previous studies ([@saue2000]).

The present study was implemented in patients who underwent LAVH and demonstrated findings similar to those of a previous study ([@bart2002]), which also reported on a laparoscopy procedure; hence, the present study suggests that other patients scheduled for laparoscopy procedure also benefit from parecoxib administration and additional oxycodone for treating visceral pain.

The present study had some limitations, such as the lack of power to demonstrate differences in the secondary outcomes. Furthermore, for optimal comparison, it would have been ideal to maintain the same administration timings for parecoxib and methylprednisolone.

Conclusion {#s5}
==========

Intraoperative parecoxib administration significantly shortened the duration of pain and reduced the intensity of patient-reported pain after LAVH. This effect cannot be duplicated following the administration of methylprednisolone, although methylprednisolone significantly lowered the postoperative CRP levels. The CRP and TNF-α levels and pain durations are not correlated. Further research on the correlation between systemic inflammation and the pain process is warranted.
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